Immunomic Therapeutics Inc. has obtained clinical trial notification (CTN) clearance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for ITI-9001, an investigational immunotherapy for Japanese red cedar allergy. The first-in-human phase I trial will begin in Japan in the second quarter.
Integrin alpha-5 (ITGA5) is a central modulator of extracellular matrix signaling and has been tied to fibrosis and tissue damage, contributing to lupus nephritis (LN) pathogenesis. A group of researchers aimed to investigate the association between ITGA5 and LN and its inhibition as a potential strategy to improve renal outcomes.
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways involving complement factor 5 and its receptor (C5aR1) were overexpressed, and that a C5aR1 antagonist, avacopan, reduced the need for glucocorticoids and improved renal recovery. This led researchers to investigate the association of anti-C5aR1 antibodies with GCA and its outcomes.
Shanghai Helioson Pharmaceutical Co. Ltd. has patented molecular glue degraders comprising cereblon (CRBN) binding agents acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of autoimmune disease and cancer.
CD45RC is an isoform of protein tyrosine phosphatase receptor type C, a protein that plays a key role in regulating antigen receptor signaling in T and B cells. While it is expressed on most circulating B cells, it is only highly expressed on Th1 precursors, Th1 cells and T effector memory CD45RA+ cells (TEMRA).
Therorna Shanghai Co. Ltd. has presented data on TI-0032, an anti-CD19 CAR circular RNA therapeutic delivered by lipid nanoparticles (LNPs) for the treatment of autoimmune and hematological disorders.
Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases.
Kymera Therapeutics has developed KT-579, a potent and selective IRF5 degrader as a novel approach for treating systemic lupus erythematosus (SLE) and Sjögren disease.
Researchers at Obleno Bio Inc. have reported preclinical efficacy data for LBL-051-S3, a trispecific T-cell engager antibody targeting CD3, CD19 and BCMA, in nonhuman primate models.
At the recent European Congress of Rheumatology (EULAR) meeting in London, researchers from Antegene Corp. Ltd. presented the preclinical characterization of ATG-207, an αCD3-TGF-β bifunctional fusion protein, in models of T-cell-driven autoimmune disease.
RSS
